DMAC - Company ID 0001401040
The table below shows DiaMedica Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.08M | -$7.15M | -$6.65M | -$5.09M | -$3.89M | -$4.31M |
| Capital expenditure | $8.00K | $12.00K | $9.00K | $7.00K | $0.00 | $9.00K |
| Investing cash flow | -$2.11M | $6.62M | $4.21M | $2.51M | $2.21M | -$9.00K |
| Dividends paid | - | - | - | - |
DiaMedica Therapeutics Inc. reported operating cash flow of -$29.06M for fiscal year 2025. That is down 31.6% from -$22.08M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$3.90M (FY 2017) to -$29.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $417.00K | $91.00K | -$1.00K | -$1.00K | -$1.00K | $242.00K |